Venetoclax – pharmaceutical daily

December 8, 2020 Off

Actinium reports complete response in the Actimab-A venetoclax combination trial

Actinium Pharmaceuticals has reported 67% overall response rate in first cohort in Actimab-A Venetoclax combination trial in relapsed and refractory AML at ASH, which includes one complete response in patient with TP53 mutation and one partial response reported in patients with poor risk adverse cytogenetics with subtherapeutic dose of Actimab-A indicative of mechanistic synergy with venetoclax.

April 23, 2019 Off

Trovagene’s combo of onvansertib, venetoclax shows synergy in cell model of Venetoclax-Resistant AML

By Dino Mustafić

Dr. Mark Erlander, Chief Scientific Officer of Trovagene. “We believe the positive results of our preclinical study provides the scientific rationale for clinical investigation of this combination regimen and may lead to a new treatment option for these patients.”

March 19, 2019 Off

AbbVie puts multiple myeloma investigational treatmenttrial on hold after higher proportion of deaths was observed in the venetoclax

By Dino Mustafić

AbbVie has put on hold clinical testing venetoclax (Venclexta/Venclyxto) for the investigational treatment of multiple myeloma, which being developed by AbbVie and Roche, and jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

November 1, 2018 Off

Quicker pathway to a pivotal trial for larger patient population than planned for Actinium’s CD33

By Dino Mustafić

@ActiniumPharma moves to next stage of development for its CD33 ARC (Antibody Radiation Conjugate) Ac-225-Lintuzumab program are pivotal trial pathway for its Actimab-MDS program for Myelodysplastic Syndromes (MDS), and also in two combination trials with Venetoclax for AML.
$ATNM